Akanda Corp (AKAN) - Net Assets
Based on the latest financial reports, Akanda Corp (AKAN) has net assets worth $-11.99 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.20 Million) and total liabilities ($18.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Akanda Corp (AKAN) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.99 Million |
| % of Total Assets | -193.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 133.07 |
Akanda Corp - Net Assets Trend (2020–2025)
This chart illustrates how Akanda Corp's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Akanda Corp to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Akanda Corp (2020–2025)
The table below shows the annual net assets of Akanda Corp from 2020 to 2025. For live valuation and market cap data, see AKAN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-11.99 Million | -380.38% |
| 2024-12-31 | $4.28 Million | +211.69% |
| 2023-12-31 | $-3.83 Million | -114.23% |
| 2022-12-31 | $26.90 Million | +1321.94% |
| 2021-12-31 | $-2.20 Million | +56.25% |
| 2020-12-31 | $-5.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Akanda Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9792926100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $92.31 Million | % |
| Total Equity | $-10.79 Million | 100.00% |
Akanda Corp Competitors by Market Cap
The table below lists competitors of Akanda Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
$7.57 Million |
|
Everland Public Company Limited
BK:EVER
|
$7.57 Million |
|
Intelicanna Ltd
TA:INTL
|
$7.57 Million |
|
Premier Products Public Company Limited
BK:PPP
|
$7.57 Million |
|
Henderson European Focus Trust Plc
LSE:HET
|
$7.56 Million |
|
Metals Creek Resources Corp
V:MEK
|
$7.56 Million |
|
Wishpond Technologies Ltd
V:WISH
|
$7.56 Million |
|
PRS Reit PLC
LSE:PRSR
|
$7.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akanda Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,276,538 to -10,785,074, a change of -15,061,612 (-352.2%).
- Net loss of 45,653,948 reduced equity.
- New share issuances of 275,929 increased equity.
- Other comprehensive income increased equity by 1,583,799.
- Other factors increased equity by 28,732,608.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.65 Million | -423.31% |
| Share Issuances | $275.93K | +2.56% |
| Other Comprehensive Income | $1.58 Million | +14.69% |
| Other Changes | $28.73 Million | +266.41% |
| Total Change | $- | -352.19% |
Book Value vs Market Value Analysis
This analysis compares Akanda Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-8705.78 | $19.10 | x |
| 2021-12-31 | $-3808.69 | $19.10 | x |
| 2022-12-31 | $38816.97 | $19.10 | x |
| 2023-12-31 | $-348081.09 | $19.10 | x |
| 2024-12-31 | $256.51 | $19.10 | x |
| 2025-12-31 | $-24.03 | $19.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akanda Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17690.19%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-23.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -111569.88% | 0.00x | 0.00x | $-1.80 Million |
| 2021 | 0.00% | -19625.88% | 0.01x | 0.00x | $-7.91 Million |
| 2022 | -43.34% | -445.00% | 0.07x | 1.45x | $-14.35 Million |
| 2023 | 0.00% | -1494.18% | 0.24x | 0.00x | $-31.89 Million |
| 2024 | -95.78% | -489.57% | 0.11x | 1.85x | $-4.52 Million |
| 2025 | 0.00% | -17690.19% | 0.04x | 0.00x | $-44.58 Million |
Industry Comparison
This section compares Akanda Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $260,339,423
- Average return on equity (ROE) among peers: -21.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | N/A | $7.56 Million |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $177.38 Million |
| Akebia Ther (AKBA) | $68.12 Million | -199.28% | 3.41x | $263.59 Million |
| Alkermes Plc (ALKS) | $1.04 Billion | -15.16% | 0.88x | $7.35 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $5.18 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $263.49 Million | 12.07% | 0.07x | $190.27 Million |
| ANI Pharmaceuticals Inc (ANIP) | $457.60 Million | 4.10% | 0.98x | $1.80 Billion |
About Akanda Corp
As of August 21, 2025, Akanda Corp. was acquired by First Towers & Fiber Corp., in a reverse merger transaction. Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products. The company was incorporated in 2021 and is headquartered in Toronto, Canada.